Table 2.
HPV results in mothers and infants included in the prospective cohort study.
| Number (n = 143) |
% | (95% CI) | |
|---|---|---|---|
| Mothers' HPV-DNA status at pregnancy | |||
| Positive/Tested | 66/143 | 46.2 | (37.8–54.7) |
| Type distribution among HPV positive: | |||
| HPV 6,11 | 10 | 15.2 | |
| HPV 16 | 17 | 25.8 | |
| HPV 18 | 4 | 6.1 | |
| HPV 31 | 1 | 1.5 | |
| HPV 33 | 1 | 1.5 | |
| HPV 39 | 1 | 1.5 | |
| HPV 16 + other types | 7 | 10.6 | |
| HPV 31 + other types | 5 | 7.6 | |
| HPV 33 + other types | 1 | 1.5 | |
| HPV X | 19 | 28.8 | |
| Mothers' HPV-DNA prevalence at 6 weeks postpartum | |||
| Positive/Tested | 25/118 | 21.2 | (14.2–29.7) |
| Type distribution among HPV positive: | |||
| HPV 6,11 | 4 | 16.0 | |
| HPV 16 | 8 | 32.0 | |
| HPV 18 | 2 | 8.0 | |
| HPV 16 + other types | 2 | 8.0 | |
| HPV 18 + other types | 1 | 4.0 | |
| HPV 31 + other types | 2 | 8.0 | |
| HPV 39 + other types | 1 | 4.0 | |
| HPV X | 5 | 20.0 | |
| Infants' HPV-DNA positivity (positive/tested) | |||
| Between 0 and 6 days | 7/117 | 6.0 | (2.4–11.9) |
| 6 weeks after birth | 14/110 | 12.7 | (7.1–20.4) |
| Between 3 and 24 months | 8/88 | 9.1 | (4.0–17.1) |
| At any point (0 to 24 months) | 26/143 | 18.2 | (12.2–25.5) |
| Type distribution among HPV positive (at any point during follow-up): | |||
| HPV X | 10 | 38.5 | |
| HPV 16 | 8 | 30.8 | |
| HPV 6/11 | 6 | 23.1 | |
| HPV 18 | 1 | 3.8 | |
| HPV 31 | 1 | 3.8 | |
| Infants' HPV positivity by mother's HPV-DNA status (positive/tested) | |||
| Born to HPV negative mothers | 13/77 | 16.9 | (9.3–27.1) |
| Born to HPV positive mothers | 13/66 | 19.7 | (10.9–31.3) |
| Origin of HPV positive samples in children | |||
| Oral | 16 | 51.6 | |
| Genital | 15 | 48.4 |